ADC Therapeutics Plans 17% Workforce Reduction to Enhance Financial Flexibility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Workforce Reduction: ADC Therapeutics announced a global workforce reduction of approximately 17%, expected to generate annual savings of about $10 million, aimed at enhancing financial flexibility and supporting key value-driving initiatives for the ZYNLONTA® franchise.
- Clinical Milestones: The company is scheduled to meet with the FDA in August 2026 to discuss the potential regulatory path for ZYNLONTA in combination with rituximab for treating relapsed or refractory large B-cell lymphoma, with an sBLA submission anticipated in Q4 2026.
- Trial Progress: ADC is advancing the LOTIS-7 trial, evaluating the efficacy of ZYNLONTA in combination with glofitamab, with data expected by the end of 2026, which will support the company's further development in the lymphoma space.
- Financial Impact: While the company anticipates incurring approximately $3 million in one-time pre-tax charges for employee severance and related costs, it expects to maintain a sufficient cash runway into 2028, ensuring ongoing operations and research capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADCT
Wall Street analysts forecast ADCT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.090
Low
5.00
Averages
7.33
High
10.00
Current: 1.090
Low
5.00
Averages
7.33
High
10.00
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADC Therapeutics Plans 17% Workforce Reduction to Enhance Financial Flexibility
- Workforce Reduction: ADC Therapeutics announced a global workforce reduction of approximately 17%, expected to generate annual savings of about $10 million, aimed at enhancing financial flexibility and supporting key value-driving initiatives for the ZYNLONTA® franchise.
- Clinical Milestones: The company is scheduled to meet with the FDA in August 2026 to discuss the potential regulatory path for ZYNLONTA in combination with rituximab for treating relapsed or refractory large B-cell lymphoma, with an sBLA submission anticipated in Q4 2026.
- Trial Progress: ADC is advancing the LOTIS-7 trial, evaluating the efficacy of ZYNLONTA in combination with glofitamab, with data expected by the end of 2026, which will support the company's further development in the lymphoma space.
- Financial Impact: While the company anticipates incurring approximately $3 million in one-time pre-tax charges for employee severance and related costs, it expects to maintain a sufficient cash runway into 2028, ensuring ongoing operations and research capabilities.
See More
ADC Therapeutics Announces 17% Workforce Reduction to Enhance Financial Flexibility
- Workforce Reduction: ADC Therapeutics announced a global workforce reduction of approximately 17%, expected to generate annual savings of about $10 million, aimed at enhancing financial flexibility to support key clinical and regulatory activities.
- Clinical Milestones: The company plans to hold a meeting with the FDA in August 2026 to discuss the supplemental Biologics License Application (sBLA) for ZYNLONTA, with submission anticipated in Q4 2026, advancing the product's market entry.
- Trial Progress: ADC is advancing the LOTIS-7 trial, evaluating the efficacy of ZYNLONTA in combination with glofitamab, with data expected by the end of 2026, further expanding the product's applications.
- Financial Impact: The reorganization is expected to incur approximately $3 million in one-time pre-tax charges primarily for employee severance, yet the company anticipates a cash runway extending at least into 2028, ensuring ongoing operations.
See More
Pomerantz LLP Investigates ADC Therapeutics for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating ADC Therapeutics SA for potential securities fraud or other unlawful business practices, aiming to protect investor rights and possibly initiate a class action lawsuit.
- Clinical Trial Results: On June 3, 2026, ADC announced that its Phase 3 LOTIS-5 trial showed ZYNLONTA® extended progression-free survival by 1.4 months in patients with relapsed or refractory DLBCL, yet the treatment group experienced 27 deaths compared to only nine in the immunotherapy group, raising serious safety concerns.
- Stock Price Plunge: Following the disappointing trial results, ADC's stock price plummeted by $2.05, or 66.56%, over the next two trading sessions, closing at $1.03 per share, indicating severe market pessimism regarding the company's future.
- Legal Implications: The ongoing investigation may lead to legal repercussions for ADC, prompting investors to stay informed about developments to take timely action to safeguard their interests.
See More
Tango Therapeutics Appoints New Board Member
- New Board Appointment: Tango Therapeutics has appointed Robert Azelby to its Board of Directors, bringing over 30 years of executive management, commercial product launches, and corporate governance experience, which is expected to provide strategic guidance and industry insights to the company.
- Extensive Industry Background: Azelby currently serves on the boards of ADC Therapeutics, Autolus Therapeutics, and Cardinal Health, Inc., and previously held the position of President and CEO at Eliem Therapeutics, enhancing his influence in the biotechnology sector.
- R&D Progress: Tango is advancing its investigational PRMT5 inhibitor, Vopimetostat, through late-stage development aimed at treating pancreatic cancer patients, demonstrating the company's potential and commitment in the cancer treatment space.
- Stock Price Movement: TNGX closed at $28.50 on Monday, up 1.89%, while pre-market trading shows a slight decline of 0.04% to $28.49, reflecting market interest in the company's new appointment.
See More
Pomerantz LLP Investigates ADC Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating ADC Therapeutics SA for potential securities fraud or other unlawful business practices, aiming to protect investor rights and pursue legal remedies.
- Clinical Trial Results: On June 3, 2026, ADC announced topline data from its Phase 3 LOTIS-5 trial showing that ZYNLONTA® combined with rituximab extended progression-free survival by 1.4 months in patients with relapsed or refractory DLBCL, but resulted in 27 deaths compared to 9 in the immunotherapy group.
- Stock Price Plunge: Following the disappointing trial results, ADC's stock price fell by $2.05, or 66.56%, over the next two trading sessions, closing at $1.03 per share on June 5, 2026, reflecting market pessimism about the company's future prospects.
- Legal Implications: Pomerantz LLP, recognized for its expertise in securities class action litigation, has historically recovered multimillion-dollar damages for victims of securities fraud, indicating that this investigation could lead to significant legal consequences for ADC.
See More
Pomerantz LLP Investigates ADC Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating ADC Therapeutics SA for potential securities fraud or other unlawful business practices, aiming to protect investor rights and possibly initiate a class action lawsuit.
- Clinical Trial Results: On June 3, 2026, ADC announced that its Phase 3 LOTIS-5 trial showed ZYNLONTA® extended progression-free survival by 1.4 months in patients with relapsed or refractory DLBCL, but the treatment group experienced significantly more deaths compared to the immunotherapy arm.
- Stock Price Plunge: Following the trial results, ADC's stock price fell by $2.05, or 66.56%, over the next two trading sessions, closing at $1.03 per share on June 5, 2026, indicating strong market concerns regarding the treatment's efficacy.
- Legal Implications: The investigation could lead to legal liabilities for ADC, and if fraud is confirmed, it may have significant negative impacts on the company's reputation and future financing capabilities.
See More
ADC Therapeutics Plans 17% Workforce Reduction to Enhance Financial Flexibility
- Workforce Reduction: ADC Therapeutics announced a global workforce reduction of approximately 17%, expected to generate annual savings of about $10 million, aimed at enhancing financial flexibility and supporting key value-driving initiatives for the ZYNLONTA® franchise.
- Clinical Milestones: The company is scheduled to meet with the FDA in August 2026 to discuss the potential regulatory path for ZYNLONTA in combination with rituximab for treating relapsed or refractory large B-cell lymphoma, with an sBLA submission anticipated in Q4 2026.
- Trial Progress: ADC is advancing the LOTIS-7 trial, evaluating the efficacy of ZYNLONTA in combination with glofitamab, with data expected by the end of 2026, which will support the company's further development in the lymphoma space.
- Financial Impact: While the company anticipates incurring approximately $3 million in one-time pre-tax charges for employee severance and related costs, it expects to maintain a sufficient cash runway into 2028, ensuring ongoing operations and research capabilities.
See More
ADC Therapeutics Announces 17% Workforce Reduction to Enhance Financial Flexibility
- Workforce Reduction: ADC Therapeutics announced a global workforce reduction of approximately 17%, expected to generate annual savings of about $10 million, aimed at enhancing financial flexibility to support key clinical and regulatory activities.
- Clinical Milestones: The company plans to hold a meeting with the FDA in August 2026 to discuss the supplemental Biologics License Application (sBLA) for ZYNLONTA, with submission anticipated in Q4 2026, advancing the product's market entry.
- Trial Progress: ADC is advancing the LOTIS-7 trial, evaluating the efficacy of ZYNLONTA in combination with glofitamab, with data expected by the end of 2026, further expanding the product's applications.
- Financial Impact: The reorganization is expected to incur approximately $3 million in one-time pre-tax charges primarily for employee severance, yet the company anticipates a cash runway extending at least into 2028, ensuring ongoing operations.
See More
Pomerantz LLP Investigates ADC Therapeutics for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating ADC Therapeutics SA for potential securities fraud or other unlawful business practices, aiming to protect investor rights and possibly initiate a class action lawsuit.
- Clinical Trial Results: On June 3, 2026, ADC announced that its Phase 3 LOTIS-5 trial showed ZYNLONTA® extended progression-free survival by 1.4 months in patients with relapsed or refractory DLBCL, yet the treatment group experienced 27 deaths compared to only nine in the immunotherapy group, raising serious safety concerns.
- Stock Price Plunge: Following the disappointing trial results, ADC's stock price plummeted by $2.05, or 66.56%, over the next two trading sessions, closing at $1.03 per share, indicating severe market pessimism regarding the company's future.
- Legal Implications: The ongoing investigation may lead to legal repercussions for ADC, prompting investors to stay informed about developments to take timely action to safeguard their interests.
See More
Tango Therapeutics Appoints New Board Member
- New Board Appointment: Tango Therapeutics has appointed Robert Azelby to its Board of Directors, bringing over 30 years of executive management, commercial product launches, and corporate governance experience, which is expected to provide strategic guidance and industry insights to the company.
- Extensive Industry Background: Azelby currently serves on the boards of ADC Therapeutics, Autolus Therapeutics, and Cardinal Health, Inc., and previously held the position of President and CEO at Eliem Therapeutics, enhancing his influence in the biotechnology sector.
- R&D Progress: Tango is advancing its investigational PRMT5 inhibitor, Vopimetostat, through late-stage development aimed at treating pancreatic cancer patients, demonstrating the company's potential and commitment in the cancer treatment space.
- Stock Price Movement: TNGX closed at $28.50 on Monday, up 1.89%, while pre-market trading shows a slight decline of 0.04% to $28.49, reflecting market interest in the company's new appointment.
See More
Pomerantz LLP Investigates ADC Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating ADC Therapeutics SA for potential securities fraud or other unlawful business practices, aiming to protect investor rights and pursue legal remedies.
- Clinical Trial Results: On June 3, 2026, ADC announced topline data from its Phase 3 LOTIS-5 trial showing that ZYNLONTA® combined with rituximab extended progression-free survival by 1.4 months in patients with relapsed or refractory DLBCL, but resulted in 27 deaths compared to 9 in the immunotherapy group.
- Stock Price Plunge: Following the disappointing trial results, ADC's stock price fell by $2.05, or 66.56%, over the next two trading sessions, closing at $1.03 per share on June 5, 2026, reflecting market pessimism about the company's future prospects.
- Legal Implications: Pomerantz LLP, recognized for its expertise in securities class action litigation, has historically recovered multimillion-dollar damages for victims of securities fraud, indicating that this investigation could lead to significant legal consequences for ADC.
See More
Pomerantz LLP Investigates ADC Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating ADC Therapeutics SA for potential securities fraud or other unlawful business practices, aiming to protect investor rights and possibly initiate a class action lawsuit.
- Clinical Trial Results: On June 3, 2026, ADC announced that its Phase 3 LOTIS-5 trial showed ZYNLONTA® extended progression-free survival by 1.4 months in patients with relapsed or refractory DLBCL, but the treatment group experienced significantly more deaths compared to the immunotherapy arm.
- Stock Price Plunge: Following the trial results, ADC's stock price fell by $2.05, or 66.56%, over the next two trading sessions, closing at $1.03 per share on June 5, 2026, indicating strong market concerns regarding the treatment's efficacy.
- Legal Implications: The investigation could lead to legal liabilities for ADC, and if fraud is confirmed, it may have significant negative impacts on the company's reputation and future financing capabilities.
See More
